Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Evaluation of Female Orgasmic Disorder

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11240%2F17%3A10361087" target="_blank" >RIV/00216208:11240/17:10361087 - isvavai.cz</a>

  • Výsledek na webu

    <a href="http://dx.doi.org/10.1007/978-3-319-52539-6_14" target="_blank" >http://dx.doi.org/10.1007/978-3-319-52539-6_14</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/978-3-319-52539-6_14" target="_blank" >10.1007/978-3-319-52539-6_14</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Evaluation of Female Orgasmic Disorder

  • Popis výsledku v původním jazyce

    An important review paper on disorders of orgasm in women noted that orgasm disorder is second only to hypoactive sexual desire disorder in women&apos;s sexual disorder prevalence. A recent meta-analysis of studies (limited to English language publications published between 2000 and 2014) on the prevalence of female sexual dysfunction among premenopausal women reported an overall female orgasmic disorder prevalence of 20.9%, increasing to 25.7% when a statistical model meant to adjust for the quality of studies was applied to the analysis [2]. That meta-analysis noted substantial variability in the diagnostic criteria used for ascertaining female orgasmic disorder (including variability in the qualifying period for prevalence) and also reported that prevalence of female orgasmic disorder in Africa was highest, followed by Asia and the Middle East, with the lowest nominal prevalence in Europe and the non-European West. Optimal nationally representative sampling was used in only a minority of studies included in the meta-analyses, which raises issues of selection bias and participation bias in many studies in the review, as well as other studies pertaining to sexual function and sexual dysfunction that were not part of the review. Interestingly, the authors of the metaanalysis concluded that studies of the prevalence of orgasmic dysfunction funded by pharmaceutical companies tended to be of higher quality than other studies. The meta-analysis did not differentiate between orgasm triggers (specifics of the sexual behavior intended to induce orgasm; see discussion of the Sexual Behavior Questionnaire in the Scales section for a list of major orgasm triggers), and unfortunately many, perhaps most, studies also fail to differentiate between orgasm triggers. As should become clear in this chapter, there are substantial psychological, interpersonal, and physiological differences between women&apos;s various sexual behaviors and corresponding orgasm triggers.

  • Název v anglickém jazyce

    Evaluation of Female Orgasmic Disorder

  • Popis výsledku anglicky

    An important review paper on disorders of orgasm in women noted that orgasm disorder is second only to hypoactive sexual desire disorder in women&apos;s sexual disorder prevalence. A recent meta-analysis of studies (limited to English language publications published between 2000 and 2014) on the prevalence of female sexual dysfunction among premenopausal women reported an overall female orgasmic disorder prevalence of 20.9%, increasing to 25.7% when a statistical model meant to adjust for the quality of studies was applied to the analysis [2]. That meta-analysis noted substantial variability in the diagnostic criteria used for ascertaining female orgasmic disorder (including variability in the qualifying period for prevalence) and also reported that prevalence of female orgasmic disorder in Africa was highest, followed by Asia and the Middle East, with the lowest nominal prevalence in Europe and the non-European West. Optimal nationally representative sampling was used in only a minority of studies included in the meta-analyses, which raises issues of selection bias and participation bias in many studies in the review, as well as other studies pertaining to sexual function and sexual dysfunction that were not part of the review. Interestingly, the authors of the metaanalysis concluded that studies of the prevalence of orgasmic dysfunction funded by pharmaceutical companies tended to be of higher quality than other studies. The meta-analysis did not differentiate between orgasm triggers (specifics of the sexual behavior intended to induce orgasm; see discussion of the Sexual Behavior Questionnaire in the Scales section for a list of major orgasm triggers), and unfortunately many, perhaps most, studies also fail to differentiate between orgasm triggers. As should become clear in this chapter, there are substantial psychological, interpersonal, and physiological differences between women&apos;s various sexual behaviors and corresponding orgasm triggers.

Klasifikace

  • Druh

    C - Kapitola v odborné knize

  • CEP obor

  • OECD FORD obor

    30215 - Psychiatry

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2017

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název knihy nebo sborníku

    The Textbook of Clinical Sexual Medicine

  • ISBN

    978-3-319-52538-9

  • Počet stran výsledku

    15

  • Strana od-do

    203-217

  • Počet stran knihy

    636

  • Název nakladatele

    Springer

  • Místo vydání

    Cham

  • Kód UT WoS kapitoly